Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy
-
Published:2023-01-18
Issue:2
Volume:27
Page:337-346
-
ISSN:1091-255X
-
Container-title:Journal of Gastrointestinal Surgery
-
language:en
-
Short-container-title:J Gastrointest Surg
Author:
Ikenaga Naoki, Nakata Kohei, Hayashi Masataka, Nakamura So, Abe Toshiya, Ideno Noboru, Murakami Masatoshi, Fujimori Nao, Fujita Nobuhiro, Isoda Takuro, Baba Shingo, Ishigami Kousei, Oda Yoshinao, Nakamura MasafumiORCID
Subject
Gastroenterology,Surgery
Reference46 articles.
1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7-33. 2. Matsumoto I, Murakami Y, Shinzeki M, et al. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study. Pancreatology 2015;15:674-680. 3. Ono S, Adachi T, Ohtsuka T, et al. Predictive factors for early recurrence after pancreaticoduodenectomy in patients with resectable pancreatic head cancer: a multicenter retrospective study. Surgery 2022;172:1782-1790. 4. Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). The Lancet 2016;388:248-257. 5. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:1011-1024.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|